NCT05170269View on ClinicalTrials.gov

Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)

PHASE3TerminatedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 17, 2021

Primary Completion Date

November 19, 2023

Study Completion Date

March 29, 2024

Conditions
Congenital Cytomegalovirus Infection
Interventions
DRUG

BT097

Subjects will receive BT097 200 U per kg of maternal body weight intravenously every 2 weeks until at least GW 17

Trial Locations (5)

13353

4906, Berlin

53127

4903, Bonn

72076

4901, Tübingen

83512

4905, Wasserburg am Inn

91054

4902, Erlangen

Sponsors

Lead Sponsor

Biotest
All Listed Sponsors
lead

Biotest

INDUSTRY

NCT05170269 - Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion) | Biotech Hunter | Biotech Hunter